» Articles » PMID: 35992968

Sub-lineages of the SARS-CoV-2 Omicron Variants: Characteristics and Prevention

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2022 Aug 22
PMID 35992968
Authors
Affiliations
Soon will be listed here.
Abstract

Since the start of the coronavirus disease 2019 (COVID-19) pandemic, new variants of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) have emerged, accelerating the spread of the virus. Omicron was defined by the World Health Organization in November 2021 as the fifth "variant of concern" after Alpha, Beta, Gamma, and Delta. In recent months, Omicron has become the main epidemic strain. Studies have shown that Omicron carries more mutations than Alpha, Beta, Gamma, Delta, and wild-type, facilitating immune escape and accelerating its transmission. This review focuses on the Omicron variant's origin, transmission, main biological features, subvariants, mutations, immune escape, vaccination, and detection methods. We also discuss the appropriate preventive and therapeutic measures that should be taken to address the new challenges posed by the Omicron variant. This review is valuable to guide the surveillance, prevention, and development of vaccines and other therapies for Omicron variants. It is desirable to develop a more efficient vaccine against the Omicron variant and take more effective measures to constrain the spread of the epidemic and promote public health.

Citing Articles

High immunity and low mortality after Omicron and mass event in Cameroon despite low vaccination.

Boum Y, Matchim L, Guimsop D, Buri B, Bebell L, Jaudel Y J Public Health Afr. 2024; 15(1):649.

PMID: 39649435 PMC: 11622603. DOI: 10.4102/jphia.v15i1.649.


Clinical outcomes of Omicron infection and vaccine acceptance among pediatric liver transplant recipients: insights from a cross-sectional survey.

Zheng Z, Lu Y, Wu H, Lam P, Sun X, Song Y Virol J. 2024; 21(1):299.

PMID: 39578871 PMC: 11583437. DOI: 10.1186/s12985-024-02531-7.


XBB.1, BQ1.1 and atypical BA.4.6/XBB.1 recombinants predominate current SARS-CoV-2 Wavelets with flu-like symptoms in Cameroon: A snapshot from genomic surveillance.

Fokam J, Ngoufack Jagni Semengue E, Gouissi Anguechia D, Etame N, Takou D, Mandeng N PLOS Glob Public Health. 2024; 4(5):e0003153.

PMID: 38728356 PMC: 11086839. DOI: 10.1371/journal.pgph.0003153.


Long COVID across SARS-CoV-2 variants, lineages, and sublineages.

Padilla S, Ledesma C, Garcia-Abellan J, Garcia J, Fernandez-Gonzalez M, de la Rica A iScience. 2024; 27(4):109536.

PMID: 38585665 PMC: 10995878. DOI: 10.1016/j.isci.2024.109536.


COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.

Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani M Cell Commun Signal. 2024; 22(1):126.

PMID: 38360719 PMC: 10868124. DOI: 10.1186/s12964-023-01316-9.


References
1.
Rizzo A, Palmiotti G . SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate. Future Oncol. 2022; 18(11):1301-1302. PMC: 8826832. DOI: 10.2217/fon-2022-0024. View

2.
Clemens S, Weckx L, Clemens R, Mendes A, Ramos Souza A, Silveira M . Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022; 399(10324):521-529. PMC: 8782575. DOI: 10.1016/S0140-6736(22)00094-0. View

3.
Duan X, Shi R, Liu P, Huang Q, Wang F, Chen X . A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants. Signal Transduct Target Ther. 2022; 7(1):23. PMC: 8787029. DOI: 10.1038/s41392-022-00879-2. View

4.
Callaway E . Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887):21. DOI: 10.1038/d41586-021-03552-w. View

5.
Veneti L, Boas H, Kristoffersen A, Stalcrantz J, Bragstad K, Hungnes O . Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022; 27(4). PMC: 8796289. DOI: 10.2807/1560-7917.ES.2022.27.4.2200077. View